FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034358332> ?p ?o ?g. }

• W2034358332 endingPage "1748" @default.
• W2034358332 startingPage "1742" @default.
• W2034358332 abstract "Bivalirudin, a direct thrombin inhibitor, has been shown to reduce major bleeding and provide a better safety profile compared to unfractionated heparin (UFH) in patients undergoing percutaneous coronary intervention (PCI) through transfemoral access. Data pertaining to the clinical benefit of bivalirudin compared to UFH monotherapy in patients undergoing transradial PCI are lacking. The present study sought to compare the in-hospital net clinical adverse events, including death, myocardial infarction, target vessel revascularization, and bleeding, for these 2 antithrombotic regimens for all patients at a tertiary care, high-volume radial center. From April 2009 to February 2011, all patients treated with bivalirudin were matched by access site to those receiving UFH. The patients in the bivalirudin group (n = 125) were older (72 ± 13 years vs 66 ± 11 years; p <0.0001), more often had chronic kidney disease (51% vs 30%; p = 0.0012), and more often underwent primary PCI (30% vs 14%, p <0.0037) than the UFH-treated patients (n = 125). A radial approach was used in 71% of both groups. The baseline bleeding risk according to Mehran's score was similar in both groups (14 ± 9 vs 15 ± 8, p = 0.48). In-hospital mortality was 2% in both groups (p = 1.00). No difference in net clinical adverse events or ischemic or bleeding complications was detected between the 2 groups. Bivalirudin reduced both ischemic and bleeding events in femoral-treated patients, but no such clinical benefit was observed in the radial-treated patients. In conclusion, as periprocedural PCI bleeding avoidance strategies have become paramount to optimize the clinical benefit, the interaction between bivalirudin and radial approach deserves additional investigation. Bivalirudin, a direct thrombin inhibitor, has been shown to reduce major bleeding and provide a better safety profile compared to unfractionated heparin (UFH) in patients undergoing percutaneous coronary intervention (PCI) through transfemoral access. Data pertaining to the clinical benefit of bivalirudin compared to UFH monotherapy in patients undergoing transradial PCI are lacking. The present study sought to compare the in-hospital net clinical adverse events, including death, myocardial infarction, target vessel revascularization, and bleeding, for these 2 antithrombotic regimens for all patients at a tertiary care, high-volume radial center. From April 2009 to February 2011, all patients treated with bivalirudin were matched by access site to those receiving UFH. The patients in the bivalirudin group (n = 125) were older (72 ± 13 years vs 66 ± 11 years; p <0.0001), more often had chronic kidney disease (51% vs 30%; p = 0.0012), and more often underwent primary PCI (30% vs 14%, p <0.0037) than the UFH-treated patients (n = 125). A radial approach was used in 71% of both groups. The baseline bleeding risk according to Mehran's score was similar in both groups (14 ± 9 vs 15 ± 8, p = 0.48). In-hospital mortality was 2% in both groups (p = 1.00). No difference in net clinical adverse events or ischemic or bleeding complications was detected between the 2 groups. Bivalirudin reduced both ischemic and bleeding events in femoral-treated patients, but no such clinical benefit was observed in the radial-treated patients. In conclusion, as periprocedural PCI bleeding avoidance strategies have become paramount to optimize the clinical benefit, the interaction between bivalirudin and radial approach deserves additional investigation." @default.
• W2034358332 created "2016-06-24" @default.
• W2034358332 creator A5008447290 @default.
• W2034358332 creator A5040379703 @default.
• W2034358332 creator A5040812704 @default.
• W2034358332 creator A5046485954 @default.
• W2034358332 creator A5046945534 @default.
• W2034358332 creator A5056836059 @default.
• W2034358332 creator A5063978497 @default.
• W2034358332 creator A5064778694 @default.
• W2034358332 creator A5065046429 @default.
• W2034358332 creator A5067929031 @default.
• W2034358332 creator A5068503721 @default.
• W2034358332 creator A5069183541 @default.
• W2034358332 creator A5070108007 @default.
• W2034358332 creator A5081584744 @default.
• W2034358332 date "2012-12-01" @default.
• W2034358332 modified "2023-10-18" @default.
• W2034358332 title "Benefit of Bivalirudin Versus Heparin After Transradial and Transfemoral Percutaneous Coronary Intervention" @default.
• W2034358332 cites W1421247184 @default.
• W2034358332 cites W1540336317 @default.
• W2034358332 cites W1573872903 @default.
• W2034358332 cites W1964365503 @default.
• W2034358332 cites W1971519115 @default.
• W2034358332 cites W1990864736 @default.
• W2034358332 cites W1994201468 @default.
• W2034358332 cites W2003027470 @default.
• W2034358332 cites W2004110783 @default.
• W2034358332 cites W2010936821 @default.
• W2034358332 cites W2019002307 @default.
• W2034358332 cites W2024376801 @default.
• W2034358332 cites W2081047245 @default.
• W2034358332 cites W2081590915 @default.
• W2034358332 cites W2088834510 @default.
• W2034358332 cites W2098325125 @default.
• W2034358332 cites W2099409915 @default.
• W2034358332 cites W2102296549 @default.
• W2034358332 cites W2121251309 @default.
• W2034358332 cites W2122779695 @default.
• W2034358332 cites W2128494024 @default.
• W2034358332 cites W2130182394 @default.
• W2034358332 cites W2133099183 @default.
• W2034358332 cites W2143763771 @default.
• W2034358332 cites W2154879358 @default.
• W2034358332 cites W2156927593 @default.
• W2034358332 cites W2887180359 @default.
• W2034358332 doi "https://doi.org/10.1016/j.amjcard.2012.07.043" @default.
• W2034358332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22980964" @default.
• W2034358332 hasPublicationYear "2012" @default.
• W2034358332 type Work @default.
• W2034358332 sameAs 2034358332 @default.
• W2034358332 citedByCount "18" @default.
• W2034358332 countsByYear W20343583322013 @default.
• W2034358332 countsByYear W20343583322014 @default.
• W2034358332 countsByYear W20343583322015 @default.
• W2034358332 countsByYear W20343583322016 @default.
• W2034358332 countsByYear W20343583322017 @default.
• W2034358332 countsByYear W20343583322022 @default.
• W2034358332 crossrefType "journal-article" @default.
• W2034358332 hasAuthorship W2034358332A5008447290 @default.
• W2034358332 hasAuthorship W2034358332A5040379703 @default.
• W2034358332 hasAuthorship W2034358332A5040812704 @default.
• W2034358332 hasAuthorship W2034358332A5046485954 @default.
• W2034358332 hasAuthorship W2034358332A5046945534 @default.
• W2034358332 hasAuthorship W2034358332A5056836059 @default.
• W2034358332 hasAuthorship W2034358332A5063978497 @default.
• W2034358332 hasAuthorship W2034358332A5064778694 @default.
• W2034358332 hasAuthorship W2034358332A5065046429 @default.
• W2034358332 hasAuthorship W2034358332A5067929031 @default.
• W2034358332 hasAuthorship W2034358332A5068503721 @default.
• W2034358332 hasAuthorship W2034358332A5069183541 @default.
• W2034358332 hasAuthorship W2034358332A5070108007 @default.
• W2034358332 hasAuthorship W2034358332A5081584744 @default.
• W2034358332 hasConcept C126322002 @default.
• W2034358332 hasConcept C164705383 @default.
• W2034358332 hasConcept C197934379 @default.
• W2034358332 hasConcept C2776301958 @default.
• W2034358332 hasConcept C2776710957 @default.
• W2034358332 hasConcept C2777015399 @default.
• W2034358332 hasConcept C2777557582 @default.
• W2034358332 hasConcept C2777565915 @default.
• W2034358332 hasConcept C2778810321 @default.
• W2034358332 hasConcept C2779161974 @default.
• W2034358332 hasConcept C2779464278 @default.
• W2034358332 hasConcept C2780400711 @default.
• W2034358332 hasConcept C45393284 @default.
• W2034358332 hasConcept C500558357 @default.
• W2034358332 hasConcept C71924100 @default.
• W2034358332 hasConceptScore W2034358332C126322002 @default.
• W2034358332 hasConceptScore W2034358332C164705383 @default.
• W2034358332 hasConceptScore W2034358332C197934379 @default.
• W2034358332 hasConceptScore W2034358332C2776301958 @default.
• W2034358332 hasConceptScore W2034358332C2776710957 @default.
• W2034358332 hasConceptScore W2034358332C2777015399 @default.
• W2034358332 hasConceptScore W2034358332C2777557582 @default.
• W2034358332 hasConceptScore W2034358332C2777565915 @default.
• W2034358332 hasConceptScore W2034358332C2778810321 @default.
• W2034358332 hasConceptScore W2034358332C2779161974 @default.

• next